|
Esophageal Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
|
25825497 |
2015 |
|
Malignant neoplasm of esophagus
|
0.300 |
Biomarker
|
disease |
CTD_human |
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
|
25825497 |
2015 |
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, our data indicated that the inhibition or knockdown SMYD2 inhibit tumor sphere formation and reduce cell migration in NSCLC/CDDP cells, but not in NSCLC parental cells.
|
31106145 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, SMYD2 mRNA expression levels were associated with the RFS of patients with BC with metastatic relapse, and SMYD4 may serve as a tumor suppressor in patients with BC, as patients with increased SMYD4 mRNA expression levels had significantly better RFS compared with decreased SMYD4 mRNA expression levels.
|
30930987 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High SMYD2 expression correlated with a high TNM stage (P = 0.007) and early tumor relapse (P = 0.032).
|
31754403 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Silencing of SMYD2 by RNAi in triple-negative breast cancer (TNBC) cell lines or inhibition of SMYD2 with its specific inhibitor, AZ505, significantly reduced tumor growth in vivo.
|
29487338 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Using 2 PTC cell lines, K1 and B-CPAP, we demonstrated that high expression of SMYD2 can promote tumor cell proliferation.
|
30319138 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Positive expression of SMYD2 was correlated with tumor size, vascular invasion, differentiation and TNM stage (<i>P</i> < 0.05).
|
29344279 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Our results shed light on a novel mechanism that modulates the kinase activity of the ALK fused gene product and imply that SMYD2-mediated ALK methylation might be a promising target for development of a novel class of treatment for tumors with the ALK fused gene.
|
28370702 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In nonmultiple cases, patients with SMYD2-overexpressing tumors had a worse overall survival rate than did those with nonexpressing tumors (P = .017, log-rank test), and SMYD2 positivity was independently associated with overall survival in the multivariate analysis (P = .003).
|
26826421 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we show that inhibition of SMYD2 cooperates with standard chemotherapy to treat PDAC cells and tumors.
|
26988419 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest that SMYD2 has a crucial role in tumor cell proliferation by its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in gastric cancer.
|
25321194 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Low expression levels of SMYD2, SETD3, and NO66 were significantly associated with shorter disease-specific and disease-free survival, especially in patients with non-organ confined tumors.
|
26488939 |
2015 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
High expression of SET and MYND domain-containing protein 2(<i>SMYD2</i>) has been reported as a poor prognostic factor for various types of cancer.
|
31612757 |
2020 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
High expression of SET and MYND domain-containing protein 2(<i>SMYD2</i>) has been reported as a poor prognostic factor for various types of cancer.
|
31612757 |
2020 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Then, we discuss the discovery, structure, inhibitors, roles, and molecular mechanisms of SMYD2 in distinct diseases, with a focus on cardiovascular disease and cancer.
|
31370883 |
2019 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
We first used the bioinformatics website to screen the data of cervical cancer in (The Cancer Genome Atlas) TCGA and survival analysis was used to find the different survival rates in the SMYD2 high expression group and low expression group.
|
31548876 |
2019 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
SET and MYND domain-containing protein 2 (SMYD2-OE) plays an important role in cancer development through methylating histone and non-histone proteins.
|
31040701 |
2019 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
SET and MYND domain-containing protein 2 (SMYD2-OE) plays an important role in cancer development through methylating histone and non-histone proteins.
|
31040701 |
2019 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
We first used the bioinformatics website to screen the data of cervical cancer in (The Cancer Genome Atlas) TCGA and survival analysis was used to find the different survival rates in the SMYD2 high expression group and low expression group.
|
31548876 |
2019 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Then, we discuss the discovery, structure, inhibitors, roles, and molecular mechanisms of SMYD2 in distinct diseases, with a focus on cardiovascular disease and cancer.
|
31370883 |
2019 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Our data demonstrate the association of a residual expression of SMYD2 and SMYD3 with CLL progression indicators and suggests both genes are regulated by a common transcriptional control in this type of cancer.
|
26790435 |
2016 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The SET and MYND domain-containing protein 2 (SMYD2), a lysine methyltransferase for histone H3K36 and p53K370, that regulates transcription was previously found to be a cancer-promoting gene in esophageal squamous cell carcinoma.
|
26826421 |
2016 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Our data demonstrate the association of a residual expression of SMYD2 and SMYD3 with CLL progression indicators and suggests both genes are regulated by a common transcriptional control in this type of cancer.
|
26790435 |
2016 |